Kwangdong Pharmaceutical광동제약
009290 · KOSPI · ₩009290 · 광동제약
₩6,360▼ ₩90 (1.40%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩1.7T | ₩1.6T | ₩1.5T | ₩1.4T | ₩1.3T |
| Cost of sales | ₩1.4T | ₩1.3T | ₩1.2T | ₩1.1T | ₩1.1T |
| Gross profit | ₩301B | ₩299B | ₩300B | ₩282B | ₩274B |
| Operating income | ₩31B | ₩30B | ₩42B | ₩38B | ₩45B |
| Net income | ₩21B | ₩42B | ₩39B | ₩27B | ₩26B |
| Net income to shareholders | ₩21B | ₩40B | ₩37B | ₩24B | ₩24B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩1.3T | ₩1.2T | ₩1.1T | ₩932B | ₩884B |
| Current assets | ₩718B | ₩719B | ₩665B | ₩606B | ₩588B |
| Cash and equivalents | ₩141B | ₩116B | ₩77B | ₩104B | ₩84B |
| Total liabilities | ₩609B | ₩552B | ₩490B | ₩385B | ₩357B |
| Current liabilities | ₩526B | ₩461B | ₩457B | ₩354B | ₩325B |
| Borrowings | ₩306B | ₩289B | — | ₩138B | ₩132B |
| Total equity | ₩712B | ₩618B | ₩588B | ₩547B | ₩527B |
| Shareholders' equity | ₩656B | ₩579B | ₩545B | ₩517B | ₩499B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩82B | −₩12B | −₩12B | ₩63B | ₩55B |
| Capital spending | ₩25B | ₩76B | ₩35B | ₩25B | ₩24B |
| Free cash flow | ₩57B | −₩88B | −₩47B | ₩38B | ₩31B |
| Dividends paid | ₩3.9B | ₩4B | ₩4.1B | ₩0 | ₩4.1B |
Consolidated where available. Amounts in won.
Also known as: Kwangdong Pharmaceutical / 광동제약 / 009290 / KRX:009290
Source: KRX statistical information